{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:25:38Z","timestamp":1778941538920,"version":"3.51.4"},"reference-count":129,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. Most of the patients of PDAC present at later stages of disease and have a five-year survival rate of less than 10%. About 5\u201310% PDAC cases are hereditary in nature and have DNA damage repair (DDR) mutations such as BRCA 1 and 2. Besides having implications on screening and prevention strategies, these mutations can confer sensitivity to platinum-based therapies and determine eligibility for poly(ADP-ribose) polymerase inhibitors (PARPi). In the presence of DDR mutations and PARPi, the cells are unable to utilize the error-free process of homologous recombination repair, leading to accumulation of double stranded DNA breaks and cell death eventually. Various PARPi are in clinical development in PDAC in different subgroup of patients as monotherapies and in combination with other therapeutics. This review would focus on the mechanism of action of PARPi, history of development in PDAC, resistance mechanisms and future directions.<\/jats:p>","DOI":"10.3390\/cancers11121980","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T11:22:51Z","timestamp":1575890571000},"page":"1980","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications"],"prefix":"10.3390","volume":"11","author":[{"given":"Medhavi","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renuka","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of GI Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Fountzilas","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of GI Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.3748\/wjg.v18.i33.4533","article-title":"FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts","volume":"18","author":"Neuzillet","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial","volume":"387","author":"Li","year":"2016","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","article-title":"A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer","volume":"101","author":"Yoo","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_8","unstructured":"(2019, August 17). Research C for DE and FDA Grants Accelerated Approval to Pembrolizumab for First Tissue\/Site Agnostic Indication. FDA, Available online: http:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"ref_9","unstructured":"(2019, August 17). Research C for DE and FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions. FDA, Available online: http:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1126\/science.1171202","article-title":"Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/ejhg.2010.198","article-title":"Prevalence of CDKN2A mutations in pancreatic cancer patients: Implications for genetic counseling","volume":"19","author":"McWilliams","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0002-9440(10)65440-5","article-title":"Germline and somatic mutations of the STK11\/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers","volume":"154","author":"Su","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_13","first-page":"738","article-title":"Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer","volume":"7","author":"Tersmette","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma","volume":"33","author":"Holter","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer","volume":"121","author":"Kelsen","year":"2015","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","article-title":"Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations","volume":"10","author":"Dedes","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): Novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrm2851","article-title":"Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis","volume":"11","author":"Moynahan","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dnarep.2014.01.009","article-title":"Non-homologous end joining: Emerging themes and unanswered questions","volume":"17","author":"Radhakrishnan","year":"2014","journal-title":"DNA Repair (Amst.)"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/283593a0","article-title":"(ADP-ribose)n participates in DNA excision repair","volume":"283","author":"Durkacz","year":"1980","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.molcel.2015.01.034","article-title":"Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance","volume":"58","author":"Bai","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1093\/nar\/gkg761","article-title":"A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage","volume":"31","author":"Masutani","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/MCB.18.6.3563","article-title":"XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage","volume":"18","author":"Masson","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1126\/science.1177321","article-title":"Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1","volume":"325","author":"Ahel","year":"2009","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1093\/nar\/gkn771","article-title":"Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes","volume":"36","author":"Gagne","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1074\/jbc.M510290200","article-title":"Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase","volume":"281","author":"Oka","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/356356a0","article-title":"Role of poly(ADP-ribose) formation in DNA repair","volume":"356","author":"Satoh","year":"1992","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","article-title":"The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability","volume":"25","author":"Gudmundsdottir","year":"2006","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nsmb0607-461","article-title":"RAD51, BRCA2 and DNA repair: A partial resolution","volume":"14","author":"Lord","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"16441","DOI":"10.1074\/jbc.M608406200","article-title":"Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents","volume":"282","author":"Haince","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1074\/jbc.M706734200","article-title":"PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites","volume":"283","author":"Haince","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Callen","year":"2016","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2008.18.5546","article-title":"BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma","volume":"27","author":"Ferrone","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_38","first-page":"e60","article-title":"BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian","volume":"7","author":"Friedenson","year":"2005","journal-title":"Medscape Gen. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","article-title":"Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura","volume":"31","author":"Dobzhansky","year":"1946","journal-title":"Genetics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMra0809889","article-title":"Susceptibility pathways in Fanconi\u2019s anemia and breast cancer","volume":"362","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1200\/JCO.2015.61.6961","article-title":"Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer","volume":"33","author":"Carnevale","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00087","article-title":"Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy","volume":"2","author":"Shahda","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.3389\/fonc.2013.00301","article-title":"Structural Implications for Selective Targeting of PARPs","volume":"3","author":"Steffen","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_51","first-page":"4175","article-title":"Novel inhibitors of poly(ADP-ribose) polymerase\/PARP1 and PARP2 identified using a cell-based screen in yeast","volume":"61","author":"Perkins","year":"2001","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e17049","DOI":"10.1200\/JCO.2016.34.15_suppl.e17049","article-title":"A phase I dose-escalation study of BGB-290, a novel PARP1\/2 selective inhibitor in patients with advanced solid tumors","volume":"34","author":"Lickliter","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Ledermann","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1\/2-Mutated Ovarian Carcinoma or Other Solid Tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","article-title":"A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation\u2014An NRG Oncology\/Gynecologic Oncology Group study","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1158\/1078-0432.CCR-15-0652","article-title":"Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors","volume":"22","author":"LoRusso","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00316","article-title":"Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation","volume":"2","author":"Shroff","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","article-title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","volume":"89","author":"Lowery","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1200\/JCO.2018.36.4_suppl.297","article-title":"Phase II study of olaparib for BRCAness phenotype in pancreatic cancer","volume":"36","author":"Golan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"CT234","DOI":"10.1158\/1538-7445.AM2019-CT234","article-title":"Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2","volume":"79","author":"Binder","year":"2019","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e4014","DOI":"10.1200\/JCO.2019.37.15_suppl.4014","article-title":"Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513","volume":"37","author":"Chiorean","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e4015","DOI":"10.1200\/JCO.2019.37.15_suppl.4015","article-title":"Final report of a phase I\/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC)","volume":"37","author":"Pishvaian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1\/2 Mutations and Selected Sporadic Cancers","volume":"7","author":"Ramanathan","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"TPS4168","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4168","article-title":"Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial","volume":"37","author":"Kasi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1158\/1078-0432.CCR-09-0910","article-title":"Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity","volume":"15","author":"Melisi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1200\/JCO.2018.36.4_suppl.314","article-title":"A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors","volume":"36","author":"Turk","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"TPS4144","DOI":"10.1200\/jco.2013.31.15_suppl.tps4144","article-title":"Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC)","volume":"31","author":"Lowery","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/1535-7163.MCT-09-0016","article-title":"Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity","volume":"8","author":"Pfister","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1074\/jbc.M111.296475","article-title":"Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes","volume":"287","author":"Patel","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1440-1746.2006.04496.x","article-title":"Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells","volume":"22","author":"Jacob","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdu581","article-title":"Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\/metastatic pancreatic cancer","volume":"26","author":"Bendell","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.molonc.2012.10.002","article-title":"Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity","volume":"7","author":"Porcelli","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tranon.2014.04.003","article-title":"Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888","volume":"7","author":"Tuli","year":"2014","journal-title":"Transl. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer","volume":"109","author":"Parkes","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.4049\/jimmunol.1101313","article-title":"Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing","volume":"188","author":"Simmons","year":"2012","journal-title":"J. Immunol. (Baltim. Md. 1950)"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1158\/0008-5472.CAN-12-3788","article-title":"Interferon-alpha suppresses cAMP to disarm human regulatory T cells","volume":"73","author":"Bacher","year":"2013","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1200\/JCO.2016.34.15_suppl.3015","article-title":"Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women\u2019s cancers (NCT02484404)","volume":"34","author":"Lee","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1200\/JCO.2019.37.4_suppl.140","article-title":"An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer","volume":"37","author":"Bang","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e1011","DOI":"10.1200\/JCO.2018.36.15_suppl.1011","article-title":"TOPACIO\/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial","volume":"36","author":"Vinayak","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1186\/s40425-019-0680-3","article-title":"A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses","volume":"7","author":"Zimmer","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"TPS4161","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4161","article-title":"A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy","volume":"37","author":"Reiss","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eaal5148","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/j.ejca.2007.07.010","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis","volume":"43","author":"Tentori","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J. Pathol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.molcel.2009.06.037","article-title":"A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency","volume":"35","author":"Cao","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.4161\/cc.22026","article-title":"Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment","volume":"11","author":"Oplustilova","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.dnarep.2013.02.003","article-title":"Identification of miRNA modulators to PARP inhibitor response","volume":"12","author":"Neijenhuis","year":"2013","journal-title":"DNA Repair (Amst.)"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The Cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Dev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1535-7163.MCT-15-0660","article-title":"A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition","volume":"15","author":"Alagpulinsa","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1158\/1538-7445.AM2018-337","article-title":"Abstract 337: The PARP inhibitor olaparib is synergistic with the ATR inhibitor AZD6738 in ATM deficient cancer cells","volume":"78","author":"Lloyd","year":"2018","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"CT025","DOI":"10.1158\/1538-7445.AM2019-CT025","article-title":"Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation","volume":"79","author":"Hamilton","year":"2019","journal-title":"Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4032","article-title":"Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat. Med."},{"key":"ref_120","first-page":"608","article-title":"Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells","volume":"9","author":"Han","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/neuonc\/nou058","article-title":"Role of AKT signaling in DNA repair and clinical response to cancer therapy","volume":"16","author":"Liu","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-15-3240","article-title":"The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models","volume":"76","author":"Rulten","year":"2016","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"202","DOI":"10.6004\/jnccn.2019.0014","article-title":"Pancreatic Adenocarcinoma, Version 1.2019","volume":"17","author":"Tempero","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"43653","DOI":"10.18632\/oncotarget.17613","article-title":"Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting","volume":"8","author":"Dougherty","year":"2017","journal-title":"Oncotarget"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e4000","DOI":"10.1200\/JCO.2018.36.15_suppl.4000","article-title":"FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX)","volume":"36","author":"Dahan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_129","first-page":"305","article-title":"Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation","volume":"9","author":"Chalasani","year":"2008","journal-title":"Jop"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/12\/1980\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:40:45Z","timestamp":1760190045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/12\/1980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":129,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["cancers11121980"],"URL":"https:\/\/doi.org\/10.3390\/cancers11121980","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,9]]}}}